These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1095 related articles for article (PubMed ID: 29576222)

  • 21. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
    Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
    Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CD39
    Zou F; Tan J; Liu T; Liu B; Tang Y; Zhang H; Li J
    Mol Ther; 2021 May; 29(5):1794-1807. PubMed ID: 33484968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis.
    Duan Z; Gao J; Zhang L; Liang H; Huang X; Xu Q; Zhang Y; Shen T; Lu F
    Oncotarget; 2015 Dec; 6(42):44239-53. PubMed ID: 26517519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
    Sakuishi K; Apetoh L; Sullivan JM; Blazar BR; Kuchroo VK; Anderson AC
    J Exp Med; 2010 Sep; 207(10):2187-94. PubMed ID: 20819927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased PD-1
    Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8
    Chen C; Zhao F; Peng J; Zhao D; Xu L; Li H; Ma S; Peng X; Sheng X; Sun Y; Wang T; Dong H; Ding Y; Wu Z; Liang X; Gao L; Wang H; Ma C; Li C
    Cell Rep Med; 2024 Aug; 5(8):101686. PubMed ID: 39168104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
    Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
    Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+Treg cells in advanced HBV-HCC.
    Yan F; Zhu B; Shi K; Zhang Y; Zeng X; Zhang Q; Yang Z; Wang X
    Cancer Sci; 2024 Aug; 115(8):2553-2564. PubMed ID: 38877825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer.
    Nakano M; Ito M; Tanaka R; Yamaguchi K; Ariyama H; Mitsugi K; Yoshihiro T; Ohmura H; Tsuruta N; Hanamura F; Sagara K; Okumura Y; Nio K; Tsuchihashi K; Arita S; Kusaba H; Akashi K; Baba E
    Cancer Sci; 2018 Sep; 109(9):2986-2992. PubMed ID: 30187676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
    Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
    Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) regulate CD4+ T cells to induce Type 2 helper T cell (Th2) bias at the maternal-fetal interface.
    Wang S; Zhu X; Xu Y; Zhang D; Li Y; Tao Y; Piao H; Li D; Du M
    Hum Reprod; 2016 Apr; 31(4):700-11. PubMed ID: 26908841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients.
    Li FJ; Zhang Y; Jin GX; Yao L; Wu DQ
    Immunol Lett; 2013 Feb; 150(1-2):116-22. PubMed ID: 23261718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.
    Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M
    J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 40. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.